Benjamin Shum
Impact in
- Infectious Diseases top 10%
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Oncology top 10%
- Cancer Immunotherapy and Biomarkers
- COVID-19 and healthcare impacts
Papers in
- Oncology 13
- Cancer Immunotherapy and Biomarkers 8
- COVID-19 and healthcare impacts 6
- Pancreatic and Hepatic Oncology Research 2
-
- SARS-CoV-2 and COVID-19 Research 8
- COVID-19 Clinical Research Studies 7
- Co-authors
- Samra Turajlic (6 shared papers)James Larkin (5 shared papers)Lewis Au (3 shared papers)David James Pinato (1 shared paper)Robert David Goldin (1 shared paper)Charalambos Gustav Antoniades (1 shared paper)Paul Nathan (1 shared paper)Tong Liu (1 shared paper)
- Journals
- Cancer Cell (4 papers)Nature Cancer (2 papers)Nature (2 papers)Cancer Discovery (1 paper)Nature Medicine (1 paper)
- Partner nations
- United KingdomNetherlands
In The Last Decade
Benjamin Shum
21 papers receiving 914 citations
Peers
Comparison fields: 5 of 63
- Infectious Diseases 302
- Oncology 413
- Cancer Research 109
- Immunology 155
- Pulmonary and Respiratory Medicine 162
Countries citing papers authored by Benjamin Shum
This map shows the geographic impact of Benjamin Shum's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Benjamin Shum with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Benjamin Shum more than expected).
Fields of papers citing papers by Benjamin Shum
This network shows the impact of papers produced by Benjamin Shum. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Benjamin Shum. The network helps show where Benjamin Shum may publish in the future.
Co-authors
The 25 scholars most cited alongside Benjamin Shum, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 22 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2021 | 187 | |
| 2 | 2021 | 140 | |
| 3 | 2021 | 90 | |
| 4 | 2021 | 82 | |
| 5 | 2021 | 69 | |
| 6 | 2020 | 63 | |
| 7 | Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer | 2022 | 60 |
| 8 | 2021 | 52 | |
| 9 | 2021 | 47 | |
| 10 | 2023 | 36 | |
| 11 | 2022 | 19 | |
| 12 | 2022 | 17 | |
| 13 | 2022 | 14 | |
| 14 | 2021 | 11 | |
| 15 | 2023 | 9 | |
| 16 | 2022 | 7 | |
| 17 | 2023 | 6 | |
| 18 | 2023 | 6 | |
| 19 | 2025 | 3 | |
| 20 | CAPTURE: Cancer and COVID-19 antiviral immune monitoring study | 2020 | 1 |
About Benjamin Shum
Benjamin Shum is a scholar working on Oncology, Infectious Diseases, Cancer Research, Immunology and Pulmonary and Respiratory Medicine, having authored 22 papers that have together received 920 indexed citations. Recurring topics across this work include SARS-CoV-2 and COVID-19 Research (8 papers), Cancer Immunotherapy and Biomarkers (8 papers), COVID-19 Clinical Research Studies (7 papers), Cancer Genomics and Diagnostics (6 papers), COVID-19 and healthcare impacts (6 papers), Immunotherapy and Immune Responses (3 papers), Pancreatic and Hepatic Oncology Research (2 papers) and Renal cell carcinoma treatment (2 papers). The work is most often cited by research in Infectious Diseases (302 citations), Oncology (413 citations), Cancer Research (109 citations), Immunology (155 citations) and Pulmonary and Respiratory Medicine (162 citations). Benjamin Shum has collaborated with scholars based in United Kingdom and Netherlands. Frequent co-authors include Samra Turajlic, James Larkin, Lewis Au, David James Pinato, Robert David Goldin, Charalambos Gustav Antoniades, Paul Nathan, Tong Liu, Cathrin L. C. Gudd and Rooshi Nathwani. Their work appears in journals such as Cancer Cell, Nature Cancer, Nature, Cancer Discovery and Nature Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.